Circulating vitamin D travels through the bloodstream almost entirely in a carrier-bound form — roughly 85-90% of the 25-hydroxyvitamin D 25(OH)D¹¹ 25(OH)D
The major circulating form of vitamin D measured by standard blood tests. It reflects total body vitamin D stores and is the number your doctor reports your doctor measures is hitched to vitamin D binding protein (VDBP)²² vitamin D binding protein (VDBP)
Also called group-specific component, or GC. A 58-kDa glycoprotein produced in the liver that is the primary transporter of vitamin D metabolites in blood. VDBP concentration and binding affinity are the two largest determinants of total circulating 25(OH)D, encoded by the GC gene on chromosome 4. The GC locus is the single strongest genetic determinant of circulating 25(OH)D in genome-wide studies — dwarfing contributions from vitamin D synthesis, activation, and receptor genes.

rs842999 is one of several independent intronic variants at the GC locus that tag haplotypes influencing VDBP expression level or binding efficiency. Unlike the missense variants rs7041 (Asp432Glu) and rs4588 (Thr436Lys), which define the classical Gc1f, Gc1s, and Gc2 protein isoforms, rs842999 does not change the amino acid sequence. Instead, it marks a haplotype block associated with altered gene expression or alternative splicing — the exact regulatory mechanism has not been characterized at a molecular level. In Danish family cohorts, rs842999 and rs4588 were the two GC variants most strongly driving the gene-level association with serum 25(OH)D, suggesting the two carry partially independent information about VDBP function.

The Mechanism

rs842999 sits in an intron of the GC gene on the minus strand at GRCh38 chr4:71745973. The G allele is the reference and the population-major allele in most ancestries; the C allele is the minor allele and functions as the risk allele associated with lower 25(OH)D. Because GC encodes VDBP — the protein that determines how much total vitamin D circulates in blood — variants that reduce VDBP expression or binding affinity translate directly into lower measured 25(OH)D on standard blood tests, even when vitamin D intake or sun exposure is the same as someone without the variant.

The C allele is common in European populations (~45% allele frequency) but is effectively absent in African populations (<0.5%) and very rare in East Asian populations. This population distribution mirrors the broader pattern at the GC locus, where C-allele haplotypes at intronic tag variants (including rs842999 and rs2282679) are markedly enriched in European ancestry groups.

The Evidence

The strongest evidence comes from a series of Danish family studies examining genetic predictors of vitamin D status. In the PLoS One 2014 study by Nissen et al.³³ Nissen et al.
Nissen J et al. Common variants in CYP2R1 and GC genes predict vitamin D concentrations in healthy Danish children and adults. PLoS One, 2014 (758 participants from 201 families), rs842999 and rs4588 were specifically identified as the GC variants most responsible for the gene-level 25(OH)D association, with a dose-dependent relationship: carriers of two G-alleles had higher 25(OH)D than one-G carriers, who had higher levels than zero-G carriers.

A companion study in the same cohort, Nissen et al. Genes & Nutrition 2014⁴⁴ Nissen et al. Genes & Nutrition 2014
Nissen J et al. Real-life use of vitamin D3-fortified bread and milk during a winter season: the effects of CYP2R1 and GC genes on 25-hydroxyvitamin D concentrations in Danish families, the VitmaD study. Genes Nutr, 2014, built a 4-SNP genetic risk score from rs10741657 (CYP2R1), rs10766197 (CYP2R1), rs4588 (GC), and rs842999 (GC), counting the C/A alleles at rs842999 as risk alleles. Across 0-8 risk alleles, there was a statistically significant negative linear trend with 25(OH)D concentrations (p < 0.0001), confirming that rs842999 contributes independently to genetic vitamin D risk.

The 2015 Am J Clin Nutr study by Nissen et al.⁵⁵ Nissen et al.
Nissen J et al. Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D3-fortified bread and milk during winter in Denmark. Am J Clin Nutr, 2015 extended these findings, showing that rs842999 and rs4588 in GC jointly predict 25(OH)D levels both after UVB irradiation (simulated sun exposure) and after 6 months of consuming vitamin D3-fortified foods, suggesting the genetic effect persists regardless of the vitamin D source (endogenous vs. dietary).

In a large Arizona cohort of 1,439 participants from two colorectal neoplasia trials, Hibler et al.⁶⁶ Hibler et al.
Hibler EA et al. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev, 2012 reported that rs842999 was one of seven GC polymorphisms significantly associated with circulating 25(OH)D concentrations after adjustment (P < 0.01).

Practical Actions

Carriers of the C allele — particularly CC homozygotes — are likely to have lower baseline 25(OH)D for a given level of sun exposure and dietary intake. The practical response is the same as for other GC locus variants: check your 25(OH)D level, and if it is below the optimal range (75-100 nmol/L / 30-40 ng/mL), supplement with vitamin D3 at doses calibrated to your measured level. The key distinction from the population average is that CC carriers typically need higher maintenance doses to sustain the same 25(OH)D concentration as GG carriers. Studies using genetic risk scores that include rs842999 found that high-risk individuals show reduced responsiveness to vitamin D fortification, meaning the same supplement dose raises 25(OH)D less in CC carriers than in GG carriers.

Interactions

rs842999 is in partial linkage disequilibrium with rs2282679 (the strongest GWAS signal at the GC locus, r² varies by population) and with rs4588 (the Thr436Lys missense variant defining the Gc2 isoform). The three variants are not fully redundant — Nissen et al. showed rs842999 and rs4588 were independently selected as the top GC predictors, suggesting they tag distinct aspects of GC haplotype variation. A full vitamin D genetic risk assessment ideally includes rs842999 alongside rs4588 or rs2282679 and rs7041.

GC variants interact with CYP2R1 (rs10741657, the major vitamin D 25-hydroxylase SNP) in a way that compounds risk: individuals with risk alleles at both the synthesis step (CYP2R1) and the transport step (GC) have the lowest 25(OH)D and the least responsiveness to supplementation in the Danish studies. VDR variants (particularly rs2228570 / Fok1) modulate downstream vitamin D receptor signaling, so GC + VDR compound genotypes are worth assessing for people with persistent vitamin D insufficiency despite adequate supplementation.

Most women don't think of their eggs as requiring constant genomic maintenance, but oocytes suspended in meiotic arrest for decades are uniquely vulnerable to DNA damage accumulation. The protein encoded by INO80¹¹ INO80
Inositol-requiring 80; the ATPase catalytic subunit of the INO80 chromatin remodeling complex, which repositions nucleosomes at DNA lesion sites to expose broken DNA ends for repair machinery is one of the key guardians of this stability — and a variant in the gene's 3'UTR region has been linked to how long a woman's ovarian reserve remains functional.

The Mechanism

The INO80 complex is recruited to DNA double-strand breaks²² DNA double-strand breaks
DSBs; the most dangerous form of DNA damage, where both strands of the double helix are severed. If unrepaired, DSBs cause chromosome rearrangements or cell death within seconds of their formation. At the break site, INO80 evicts and repositions nucleosomes, unwrapping chromatin so that homologous recombination repair machinery — RAD51, BRCA1, BRCA2 — can access the damaged ends. Without adequate INO80, repair at DSBs stalls, γ-H2AX foci persist, and cells enter senescence³³ senescence
a permanent cell-cycle arrest; in follicle cells this translates directly to follicular atresia and loss of ovarian reserve.

INO80 has a second, equally critical function at telomeres. Cao et al. 2014⁴⁴ Cao et al. 2014
Cao T et al. The mINO80 chromatin remodeling complex is required for efficient telomere replication and maintenance of genome stability. Cell Res 24:1318–1331 showed that mouse cells lacking INO80 develop fragile telomeres — a signature of failed replication through telomeric repeats — leading to chromosome fusions and mitotic catastrophe. In oocytes, where telomere length correlates directly with developmental competence and embryo viability, this function is particularly consequential.

The rs9796 variant sits in the 3' untranslated region of INO80 (NM_017553.3:c.*974; GRCh38 chr15:40,979,249). This region is not translated into protein but controls mRNA stability and translation efficiency. The T allele on the plus strand (corresponding to the coding-strand A at c.*974) is associated with greater INO80 expression output — likely by disrupting an inhibitory microRNA binding site or stabilizing the mRNA 3' structure. The net effect is more INO80 protein, more efficient chromatin remodeling at damage sites, and slower oocyte attrition.

The Evidence

The primary evidence comes from the landmark 2021 GWAS of ovarian ageing. Ruth et al. 2021⁵⁵ Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393–397 analysed age at natural menopause (ANM) in approximately 200,000 women of European ancestry. The INO80 locus reached genome-wide significance with the T allele at rs9796 associated with a beta of +0.155 years per allele — meaning TT homozygotes, on average, reach menopause approximately 0.31 years (around 4 months) later than AA homozygotes. This finding placed INO80 within the dominant biological theme of the 290-locus GWAS: DNA damage response genes — rather than hormonal or metabolic pathways — are the primary determinants of how quickly the ovarian reserve is depleted.

The DNA repair connection is biologically well-supported. Human cells with depleted INO80 show impaired survival after gamma-irradiation, delayed clearance of DSB markers, and premature entry into senescence — all consistent with a direct role in maintaining the genomic integrity that long-lived primary oocytes require.

Practical Actions

The most actionable intervention informed by this variant is NAD+ precursor supplementation. NAD+ is the essential cofactor for both PARP enzymes (which sense and signal DSBs) and sirtuin deacylases (which regulate chromatin compaction at damage sites). As women age, NAD+ levels in oocytes decline substantially. Bertoldo et al. 2020⁶⁶ Bertoldo et al. 2020
NAD+ Repletion Rescues Female Fertility during Reproductive Aging. Cell Rep 30:1670–1681 demonstrated in aged mice that NMN supplementation restored NAD+ levels in oocytes, dramatically improved oocyte quality and fertilization rates, and reversed reproductive ageing markers — effects mediated partly through SIRT2 activation and improved chromosomal cohesion maintenance.

For women planning delayed conception or undergoing IVF, this translates to a genotype-informed rationale for NMN or NR supplementation, particularly in carriers of the AA genotype who lack the T allele's protective influence on INO80 expression.

Interactions

The INO80 pathway intersects with NAD+ metabolism at multiple points: PARP1 (activated by DSBs, rapidly consumes NAD+) competes directly with sirtuins for the same NAD+ pool. In conditions of high DNA damage load — chronic oxidative stress, ageing, or reduced INO80-mediated repair efficiency — PARP activation can deplete NAD+ to levels that impair sirtuin function, creating a compounding cycle of genome instability. Variants in BRCA1 (rs1799966), BRCA2 (rs80359550), and other homologous recombination genes would interact additively with reduced INO80 expression, since INO80 acts upstream of BRCA1/2 recruitment to DSBs. Carriers of additional HR pathway variants alongside the AA genotype at rs9796 represent a subgroup with the greatest need for proactive genomic maintenance support.

The R268K variant (rs1208) is often used as a tag SNP for NAT2 acetylator status because it is in strong linkage disequilibrium ¹¹ Linkage disequilibrium means nearby genetic variants tend to be inherited together as a block rather than independently with rapid acetylator haplotypes. The A allele at this position tags the NAT2*4 rapid acetylator haplotype, which is the ancestral (wild-type) form of the enzyme with full activity.

Understanding Tag SNPs

A tag SNP is a genetic variant that can serve as a proxy for a larger haplotype block. ²² A haplotype block is a set of nearby variants on the same chromosome that are almost always inherited together In the case of rs1208, the A allele reliably indicates the presence of a rapid acetylator allele, while the G allele indicates a slow acetylator allele. This makes it useful for genotyping studies where testing all NAT2 variants is not practical. Notably, the G allele is very rare in East Asian populations (~4%) but common in Europeans (~43%) and Africans (~41%).

The Bigger Picture

Your NAT2 acetylator phenotype - rapid, intermediate, or slow - has practical consequences for both environmental exposures and medication responses. Slow acetylators clear certain carcinogens (particularly aromatic amines from cigarette smoke and heterocyclic amines from cooked meat) more slowly, allowing these compounds to interact with DNA for longer periods.

Metabolic Associations

Beyond detoxification, rs1208 was identified as the lead SNP in a genome-wide association study³³ genome-wide association study
Knowles JW et al. Identification and validation of NAT2 as an insulin sensitivity gene. J Clin Invest, 2015 linking NAT2 to insulin sensitivity. The slow acetylator genotype was associated with decreased insulin sensitivity independent of BMI, and nominally associated with increased fasting glucose, HbA1c, total and LDL cholesterol, triglycerides, and coronary artery disease risk.

Balancing Risks

Interestingly, slow acetylation is not universally bad. While slow acetylators have higher bladder cancer risk from smoking, rapid acetylators have higher colorectal cancer risk from well-done meat. This is because NAT2 can both activate and deactivate different carcinogens depending on the substrate. ⁴⁴ NAT2 can either detoxify a carcinogen or convert a pro-carcinogen into its active, DNA-damaging form The practical takeaway is universal: minimize exposure to both cigarette smoke and heavily charred meats regardless of your acetylator status.

Your airways rely on a rapid alarm system. When epithelial cells lining the bronchi are damaged by allergens, viruses, or pollutants, they release a signalling protein called IL-33 (interleukin-33)¹¹ IL-33 (interleukin-33)
An alarmin cytokine released from epithelial cell nuclei upon tissue damage; it binds the ST2 receptor on mast cells, ILC2s, eosinophils, and Th2 cells to initiate type-2 allergic inflammation — the core biology of asthma and hay fever. Several common IL33 variants are known to amplify this signal, raising asthma risk. The rs12551268 A allele appears to work in the opposite direction — a directional protective signal against childhood asthma observed in a Finnish birth cohort, though the effect has not yet reached statistical significance in the one published study.

The Mechanism

rs12551268 sits deep within intron 5 of IL33 on chromosome 9 (GRCh38 chr9:6,231,318), within an intron of the gene rather than in a coding region. The C allele is the common allele (~72% in Europeans), while the A allele is rarer (~28%). Intronic variants in this region of IL33 can influence gene expression by altering regulatory elements²² regulatory elements
DNA sequences within introns that can act as enhancers, silencers, or splice-efficiency regulators, shaping when and how much mRNA is produced from the gene or by modulating alternative splicing efficiency. The A allele may reduce IL33 mRNA output or alter the balance of full-length versus truncated isoforms — a mechanism consistent with the well-characterised protection conferred by the IL33 splice-LOF variant rs146597587³³ rs146597587
A rare splice-acceptor variant in IL33 that produces a truncated, ST2-blind IL-33 protein; carriers have 40% lower IL33 mRNA and are ~50% less likely to develop asthma (OR 0.47 in Smith et al. 2017). The precise functional mechanism of rs12551268 has not been established by experimental studies.

The Evidence

The primary evidence comes from a prospective Finnish birth cohort⁴⁴ prospective Finnish birth cohort
Teräsjärvi et al. 2024, APMIS; 146 children followed from birth to age 7 years; ST2 and IL-33 polymorphisms analysed alongside serum sST2 and IL-33 levels at 13 months and asthma diagnoses at 7 years (PMID 38566447). Among two ST2 SNPs (rs1041973, rs13408661) and three IL-33 SNPs (rs1342326, rs12551256, rs12551268) examined, children carrying variants of rs12551268 were less often diagnosed with asthma by age 7. However, the authors explicitly note that these differences were not statistically significant, a limitation expected in a cohort of 146 children.

The biological plausibility for protective IL33 intronic variants is strong. Smith et al. 2017 (PMID 28273074) demonstrated that the rare IL33 splice-LOF variant rs146597587-C reduces total IL33 mRNA by 40% and protects against asthma with OR 0.47 in over 6,400 cases. If rs12551268 influences IL33 expression even modestly in the same direction, the mechanism is identical: less IL-33 reaching mast cells, ILC2s, and eosinophils means a quieter type-2 alarm response to airway challenge.

Critically, the evidence remains at the emerging level. One birth cohort study of 146 children, with a non-significant trend, is insufficient to establish the A allele as protective with confidence. Larger GWAS and functional studies are needed to determine whether this variant acts through gene regulation, and if so, how large the effect is. The IL33 locus is densely studied in asthma genetics; this variant has not appeared in any published GWAS Catalog entry or large consortium GWAS.

Practical Actions

Because the evidence is not statistically significant and the study was small, no strong personalised interventions can be recommended based solely on rs12551268 genotype. The protective trend is consistent with a biologically coherent mechanism, but caution is warranted in interpreting an emerging signal.

For C-allele homozygotes (the common genotype, ~52% of Europeans), the full complement of IL-33 signalling is unmodified at this locus — the same IL-33 pathway considerations that apply to the general population apply here. Other IL33 and IL1RL1 variants in your profile (such as rs992969 for the major regulatory signal) provide better-established guidance for actionable steps.

Interactions

rs12551268 exists within the same IL33 locus as the well-characterised risk variant rs992969 and the rare protective LOF variant rs146597587. The ST2 receptor side of the same signalling axis is captured by rs13408661 and rs1041973 (IL1RL1). Together, these variants describe the full IL-33/ST2 pathway from ligand expression to receptor density. If rs992969 and rs12551268 are on different haplotypes, their effects on IL33 expression may partially offset or compound depending on the specific combination — though no published data model this interaction.

The insulin receptor (INSR) is the entry point for insulin signaling in every cell of the body. When insulin binds, it activates a receptor tyrosine kinase¹¹ A kinase is an enzyme that adds phosphate groups to target proteins, triggering a cascade of intracellular signals cascade that routes glucose into cells, stimulates glycogen synthesis, and suppresses glucose production by the liver. Disruption of INSR function — whether from rare mutations or common regulatory variants — is a central mechanism in insulin resistance and type 2 diabetes.

rs12610022 is an intronic variant located in intron 13 of INSR on chromosome 19p13.2. It is not a coding change and does not directly alter the insulin receptor protein sequence. Instead, as an intronic variant near a region known to harbor splicing regulatory elements, it may influence how the INSR gene is transcribed or spliced.

The Mechanism

The INSR gene produces two main protein isoforms, INSR-A and INSR-B, through alternative splicing²² Alternative splicing is a process where different exons of a gene are included or excluded from the final mRNA, producing distinct protein variants from a single gene of exon 11. INSR-B (with exon 11) is the dominant form in metabolic tissues — liver, muscle, and adipose — and mediates the classical glucose-lowering actions of insulin. INSR-A (without exon 11) has higher affinity for IGF-II and drives mitogenic rather than metabolic signaling. In type 2 diabetes, the INSR-A/INSR-B ratio is shifted toward the mitogenic isoform, reducing metabolic signal output per unit of insulin.

Intronic sequences flanking exon 11 contain splicing enhancers and silencers that control isoform balance. A variant in intron 13 — which lies downstream of the exon 11 splicing cassette — could plausibly influence secondary splicing events or INSR transcript stability, though the specific molecular effect of rs12610022 has not been experimentally confirmed. Its position in LD with functional exonic variants in the same gene (including rs2229431 in exon 13) means it may also act as a tag SNP for those nearby functional changes.

The Evidence

A sequencing study by Melkersson 2018³³ Melkersson 2018
Melkersson K. Sequencing of the insulin receptor (INSR) gene reveals association between gene variants in exon and intron 13 and schizoaffective disorder. Neuro Endocrinol Lett, 2018 conducted whole-gene INSR sequencing in 105 patients with schizophrenia or schizoaffective disorder and 60 healthy controls. The study identified rs12610022 (intron 13) as showing tendencies toward significant differences in allele and genotype distribution specifically in schizoaffective disorder patients versus controls — a finding consistent with the emerging hypothesis that impaired insulin receptor signaling in the brain contributes to psychotic illness. The study is small (165 total participants) and rs12610022 did not reach conventional GWAS thresholds independently; replication in larger cohorts is needed.

Separately, Kaminska et al. 2014⁴⁴ Kaminska et al. 2014
Kaminska D et al. Adipose tissue INSR splicing in humans associates with fasting insulin level and is regulated by weight loss. Diabetologia, 2014 demonstrated that adipose tissue expression of INSR-B correlates negatively with fasting insulin levels (p = 3×10⁻²²) across three independent cohorts, and weight loss — via bariatric surgery or caloric restriction — restores INSR-B expression. This establishes the biological plausibility that intronic regulatory variants influencing INSR isoform balance would have measurable metabolic consequences.

The G allele of rs12610022 is rare in Europeans (~6%) but substantially more common in East Asian populations (~58%), which may explain why metabolic associations have been difficult to detect in predominantly European study cohorts.

Practical Implications

For carriers of one or two G alleles, the evidence is too early for specific clinical guidance. The most actionable insight from INSR biology is that receptor sensitivity is modifiable: adipose INSR-B expression responds robustly to weight loss, meaning that reducing adipose mass directly upregulates the metabolically favorable isoform regardless of underlying genotype. Monitoring fasting insulin (rather than glucose alone) provides an earlier window into insulin signaling competence.

Interactions

rs12610022 lies in the same gene as several better-studied INSR variants. The rs2229431 exon 13 variant was the primary finding in the same Melkersson 2018 study, suggesting the intron 13 and exon 13 variants may tag a common haplotype. The widely studied rs1799817 (His1085His, exon 17) and rs2059807 have established associations with PCOS and insulin resistance in multiple ethnic populations. If you carry risk alleles at multiple INSR positions, the combined effect on receptor function warrants closer metabolic monitoring.

Every neuron, including the dopamine-producing cells of the substantia nigra¹¹ substantia nigra
The midbrain region housing dopaminergic neurons whose iron stores are consistently reduced in restless legs syndrome even when blood iron is normal, depends on a steady supply of iron to sustain normal function. But iron cannot simply diffuse into the brain — it must cross specialized barriers, and the protein that controls its export from cells along this route is ferroportin²² ferroportin
The sole known mammalian iron exporter, encoded by SLC40A1 on chromosome 2, expressed on enterocytes, macrophages, and critically the choroid plexus epithelial cells and ependymal cells lining the brain's ventricles. The rs12693542 variant sits approximately two kilobases upstream of the SLC40A1 gene in a regulatory region, where it influences how much ferroportin the cell produces. The G allele — a minority variant in most populations — is associated with increased susceptibility to restless legs syndrome³³ restless legs syndrome
Also called Willis-Ekbom disease; a neurological condition causing irresistible urges to move the legs, typically at rest and worst in the evening, affecting 5-10% of adults.

The Mechanism

Restless legs syndrome is not, as was long assumed, primarily a dopamine disorder. Post-mortem neuropathology⁴⁴ Post-mortem neuropathology
Connor JR et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003 consistently shows iron-deficient substantia nigra in RLS brains, but the cellular machinery looks normal: no dopaminergic degeneration, no Lewy bodies. The iron simply isn't getting in. The iron stores of [neuromelanin cells | Pigmented dopamine-producing neurons in the substantia nigra that normally accumulate large iron deposits through the lifespan] — which normally accumulate iron throughout life — are markedly depleted in RLS brains compared to age-matched controls.

The route iron takes into the brain is circuitous. Iron from the bloodstream enters [choroid plexus | A network of epithelial cells in the brain's ventricles that produces cerebrospinal fluid and acts as a selective iron gateway into the CNS] epithelial cells, crosses those cells, and is then exported via ferroportin into cerebrospinal fluid, which delivers iron to brain tissue. A second route crosses the blood-brain barrier microvasculature. Studies of RLS brains⁵⁵ Studies of RLS brains
Connor JR et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011 found paradoxically elevated ferroportin in the choroid plexus of RLS patients — a likely compensatory response to the iron-deficient brain environment — alongside reduced IRP1 activity, suggesting dysregulated cellular iron sensing.

Critically, laser capture microdissection⁶⁶ laser capture microdissection
Connor JR et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology, 2004 of individual neuromelanin cells from RLS substantia nigra found reduced ferroportin, reduced transferrin receptor, reduced H-ferritin, and reduced IRP1 protein — a signature of cellular iron starvation despite the compensatory upregulation at the choroid plexus. The upstream variant rs12693542 presumably modulates the baseline expression of SLC40A1, shifting the equilibrium of this already-fragile brain iron delivery system.

Hepcidin-ferroportin signaling⁷⁷ Hepcidin-ferroportin signaling
Clardy SL et al. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci, 2006 is also disrupted in RLS — pro-hepcidin was significantly decreased in CSF of early-onset RLS patients, while brain tissue showed elevated pro-hepcidin in the substantia nigra and putamen. This bidirectional hepcidin dysregulation compounds any genetically reduced ferroportin expression, creating a milieu in which the brain chronically under-delivers iron to precisely the neurons that need it.

The Evidence

The Schormair et al. 2024 meta-analysis⁸⁸ Schormair et al. 2024 meta-analysis
Schormair B et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nature Genetics, 2024 represents the definitive population genetics study of RLS to date — 116,647 cases and 1,546,466 controls of European ancestry, increasing the total genome-wide significant loci from 20 to 164. rs12693542 in the SLC40A1 regulatory region reached p=1.35×10⁻¹³, comfortably beyond genome-wide significance (p<5×10⁻⁸). This places it among the most robustly replicated common genetic risk factors for RLS, and directly implicates the ferroportin expression axis in disease pathogenesis.

The biological plausibility is high. Multiple independent lines of evidence converge: the neuropathological iron deficiency in RLS substantia nigra, the aberrant ferroportin expression at the blood-brain interface, the disrupted hepcidin-ferroportin signaling in RLS CSF and brain tissue, and now the GWAS signal upstream of the gene encoding ferroportin itself.

Practical Actions

The clinical implications follow directly from the pathophysiology. Iron therapy is an established first-line treatment for RLS when serum ferritin is low, and even in patients with "normal" peripheral iron. Current guidelines recommend iron supplementation when ferritin is below 75 µg/L, as clinical trials reviewed by Trenkwalder et al.⁹⁹ clinical trials reviewed by Trenkwalder et al.
Trenkwalder C et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 2018 demonstrate that intravenous iron preparations (ferric carboxymaltose, ferric gluconate) significantly reduce RLS symptom severity. The therapeutic target for brain iron delivery is a serum ferritin well above the lower limit of the normal reference range — typically 100-150 µg/L for optimal neurological iron availability.

Oral iron supplementation is also effective for milder cases. Iron bisglycinate is better tolerated and has higher bioavailability than ferrous sulfate. Ferritin should be monitored at 3-month intervals when supplementing to track response and avoid overcorrection.

Importantly, the brain iron deficit in RLS is not simply a mirror of peripheral iron status. Some RLS patients have normal serum ferritin yet still respond to iron therapy, suggesting that the genetic variants affecting iron transport at the blood-brain interface — including SLC40A1 regulatory variants — create a CNS-specific iron insufficiency that is only partially captured by serum ferritin.

Interactions

rs12693542 operates within the broader iron homeostasis network. Three key interaction partners are represented elsewhere in the GeneOps database:

HFE variants rs1800562 (C282Y) and rs1799945 (H63D) cause hereditary hemochromatosis by raising serum iron — paradoxically, some hemochromatosis patients can still have RLS if brain iron delivery is impaired despite elevated peripheral iron. The combination of HFE iron overload genotype with the SLC40A1 upstream risk allele (reduced ferroportin expression) creates opposing pressures on the systemic versus neurological iron axis.

TMPRSS6 rs855791 (Ala736Val) affects hepcidin suppression and iron absorption efficiency. Individuals carrying both the TMPRSS6 A allele (reduced iron absorption) and the SLC40A1 G allele (impaired brain iron delivery) face compounded disadvantage: less iron in the bloodstream to begin with, and less efficient delivery to the CNS. This compound exposure likely represents the highest-risk subgroup for RLS driven by iron insufficiency.

Adiponectin is often called the body's metabolic thermostat. Secreted exclusively by fat tissue, it circulates in the bloodstream and signals the liver and muscles to take up glucose, burn fatty acids, and remain sensitive to insulin. Low adiponectin is one of the most consistent laboratory findings in people with type 2 diabetes, metabolic syndrome, and cardiovascular disease. The rs16861194 variant sits just upstream of the ADIPOQ gene and acts like a dimmer on the gene's promoter — the G allele appears to turn the dial down.

The Mechanism

rs16861194 is located approximately 11,426 base pairs upstream of the ADIPOQ transcription start site¹¹ transcription start site
the position in DNA where RNA copying begins, placing it in the gene's promoter region — the regulatory DNA that determines how actively the gene is transcribed. The A-to-G substitution is predicted to alter transcription factor binding affinity at this promoter site, reducing ADIPOQ expression in adipocytes. Lower ADIPOQ transcription means less adiponectin protein secreted into the bloodstream. With less adiponectin available, the liver and skeletal muscle receive a weaker signal to clear glucose from the blood and oxidise fatty acids, progressively worsening insulin sensitivity over time. This upstream promoter mechanism contrasts with coding variants (like rs2241766) that alter the adiponectin protein itself; here, the protein is structurally normal but produced in smaller amounts.

The Evidence

The strongest single-study evidence comes from Wang et al. (2009), who genotyped 11 ADIPOQ-pathway variants in 985 type 2 diabetes cases and 1,050 controls in Han Chinese²² 985 type 2 diabetes cases and 1,050 controls in Han Chinese
Wang et al. Association study of the single nucleotide polymorphisms in adiponectin-associated genes with type 2 diabetes in Han Chinese. J Genet Genomics, 2009. Of all variants tested, rs16861194 was the only one reaching significance: OR=1.29 (95%CI 1.08–1.55, P=0.007). The finding was subsequently replicated in a Tunisian Arab cohort of 917 T2DM cases and 748 controls³³ 917 T2DM cases and 748 controls
Mtiraoui et al. ADIPOQ SNPs and haplotypes contribute to T2DM genetic risk in Tunisian Arabs. Diabetes Res Clin Pract, 2012, where the G allele was significantly overrepresented in cases (P<0.001) under both additive and dominant models. A meta-analysis of 8 independent studies⁴⁴ meta-analysis of 8 independent studies
Chu et al. AdipoQ polymorphisms are associated with T2DM: a meta-analysis study. Diabetes Metab Res Rev, 2013 pooled the evidence and found an OR of 1.15 (95%CI 1.04–1.27) under the additive model, with the effect most pronounced in European populations. A separate study reported that rs16861194 also associates with the systolic blood pressure response to potassium supplementation (P=0.026), suggesting its reach extends to cardiovascular-related metabolic regulation beyond glucose alone. Notably, one Chinese study found no direct relationship between rs16861194 and plasma adiponectin concentration despite hypertension associations, raising the possibility that this promoter variant's primary effect may operate through tissue-level signalling rather than simply circulating adiponectin quantity.

The overall evidence picture is moderate: the T2DM association is replicated across multiple independent populations and a meta-analysis, but effect sizes are small (OR ~1.15–1.29), not all studies find an effect, and the functional mechanism at the promoter level has not been confirmed by in-vitro reporter assays specifically for this variant.

Practical Actions

Carriers of one or two G alleles face a modestly elevated metabolic risk that responds well to evidence-based strategies targeting insulin sensitivity and glucose regulation. Monitoring fasting glucose and insulin at regular intervals provides early warning of deteriorating metabolic health. Dietary patterns that specifically raise adiponectin levels — particularly higher intake of long-chain omega-3 fatty acids (EPA and DHA from fish or algae) and magnesium-rich whole foods — are mechanistically relevant: both nutrients are documented to increase adiponectin secretion from adipose tissue. Reducing visceral adiposity is the most powerful lever for raising adiponectin, because adiponectin output per adipocyte falls sharply as cells enlarge with excess fat.

Interactions

rs16861194 sits in a haplotype block (Block 1) that includes rs4632532 and rs266729. Studies consistently analyse these as a haplotype unit, and the T2DM risk appears to be partly driven by haplotype combinations rather than rs16861194 alone. The related ADIPOQ coding variant rs2241766 (G276T) affects adiponectin protein structure and circulating levels through a different mechanism; carrying risk alleles at both loci may compound the reduction in adiponectin function. CDH13 rs4783244, which encodes the adiponectin receptor cadherin-13, is a pathway partner — impaired adiponectin signalling from reduced production (rs16861194) combined with impaired receptor-mediated uptake (rs4783244) represents a double hit on the adiponectin–insulin-sensitivity axis. Interaction with dietary potassium intake (documented effect on blood pressure response, P=0.026) suggests that potassium status may modulate the cardiovascular dimension of this variant's impact.

About 25% of all prescription medications are processed by the CYP2D6 enzyme — a figure that spans everything from opioids like codeine and tramadol to antidepressants, antipsychotics, beta-blockers, and tamoxifen. Accurate genotyping of CYP2D6 is therefore one of the highest-stakes tasks in clinical pharmacogenomics. The rs17002852 variant sits in a unique position: it doesn't alter CYP2D6 enzyme function directly, but it can disrupt the diagnostic tools used to read your CYP2D6 status — specifically the detection of the CYP2D6*3 non-functional allele.

The Mechanism

CYP2D6 is located on chromosome 22 (minus strand), and rs17002852 corresponds to a synonymous change¹¹ synonymous change
NM_000106.6:c.696T>C; plus-strand A>G at chr22:42128321 (GRCh38) at codon 696 of the CYP2D6 transcript. The amino acid at position 232 (histidine) remains unchanged — so enzyme structure and activity are unaffected by this variant alone.

The problem arises in the laboratory. Standard hydrolysis probe assays and pyrosequencing assays for CYP2D6*3 (rs35742686)²² CYP2D6*3 (rs35742686)
*3 is a frameshift deletion that abolishes CYP2D6 function are designed around the assumption that the nucleotide at the g.2470 position (rs17002852) is the common reference (A on the plus strand, T on the coding strand). When the G allele is present at rs17002852, its proximity to the *3 detection probe causes allele dropout³³ allele dropout
Allele dropout: one allele in a heterozygous sample fails to amplify or be detected, producing a false homozygous result — the affected allele is simply not detected. A person who carries CYP2D6*3 on the same chromosome as rs17002852 G may appear homozygous normal on standard assays, when they are actually a CYP2D6*3 heterozygote or compound heterozygote.

The Evidence

Scantamburlo et al. (2017)⁴⁴ Scantamburlo et al. (2017)
Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation. Cell Physiol Biochem, 43:2297–2309. genotyped 365 patient samples using three parallel methods — Sanger sequencing (gold standard), hydrolysis probe assays, and pyrosequencing. A discrepancy emerged for CYP2D6*3 detection in one sample that also carried rs17002852. The G allele frequency was 2.47% in this cohort, consistent with the global ALFA frequency of 0.74% and higher frequencies observed in Ashkenazi Jewish (~1.7%) and South Asian (~1.8%) populations. The solution was assay redesign to avoid the g.2470 position. The authors recommend intra-patient validation with at least two independent methods when rs17002852 is detected, as any single-method CYP2D6 panel may silently miss a co-inherited *3 or other nearby non-functional allele.

ClinVar records the A>G variant VCV000828876⁵⁵ VCV000828876
ClinVar drug response classification, single submission, no assertion criteria under a "drug response" classification related to tramadol metabolism — reflecting that misclassification of *3 carrier status would affect tramadol prescribing decisions, since CYP2D6*3 carriers have reduced conversion of tramadol to its active O-desmethyltramadol metabolite.

Practical Actions

Most people carrying the G allele at rs17002852 will never know they have it, and this variant itself does not change how medications work in the body. The actionable implication applies when you are undergoing CYP2D6 genotyping for clinical or pharmacogenomic purposes: standard single-method panels may miss a co-inherited CYP2D6*3 allele. If your genotyping results show this variant alongside CYP2D6*3 detection, or if you are prescribed medications with narrow therapeutic windows where CYP2D6 status matters (tramadol, codeine, tamoxifen, tricyclic antidepressants), confirmatory testing with an alternative method such as next-generation sequencing or a redesigned assay is warranted.

Interactions

This variant's clinical relevance is entirely defined by its interaction with the CYP2D6*3 allele (rs35742686). The rs17002852 G allele can occur in trans (on the opposite chromosome) from CYP2D6*3, or in cis (on the same chromosome), either combination causing the same diagnostic assay problem. Users who carry both rs17002852 G and a CYP2D6 non-functional allele on standard panels should confirm their complete CYP2D6 status with extended genotyping. See also rs3892097 (*4) and rs1065852 (*10) for the full CYP2D6 picture.

Buried in an intron of the FADS2 gene on chromosome 11, rs174575 is one of the most studied variants in human fatty acid metabolism. FADS2 encodes delta-6 desaturase¹¹ delta-6 desaturase
The enzyme that performs the first desaturation step in both the omega-6 and omega-3 elongation pathways, acting before FADS1 (delta-5 desaturase) in the cascade, the rate-limiting enzyme that initiates the conversion of short-chain dietary fats into their biologically active long-chain forms. Without adequate delta-6 desaturase activity, the pathway stalls before it can produce gamma-linolenic acid (GLA) from linoleic acid, or stearidonic acid (SDA) from alpha-linolenic acid — the precursors to all downstream omega-6 and omega-3 long-chain polyunsaturated fatty acids (LC-PUFAs) including arachidonic acid, EPA, and DHA.

The Mechanism

The rs174575 G allele acts through an intronic regulatory mechanism that reduces FADS2 enzyme expression and activity. The result is a classic substrate-product inversion: G allele carriers accumulate the upstream precursors linoleic acid (LA) and alpha-linolenic acid (ALA) while producing less of the downstream products arachidonic acid (ARA), EPA, and DHA. Because FADS2 acts at the very first desaturation step, its impairment affects both the omega-6 and omega-3 pathways simultaneously — reducing the body's ability to make any of the long-chain PUFAs from plant-based sources.

The effect is additive: each G allele further reduces desaturase activity, with GG homozygotes showing the most pronounced accumulation of precursors and reduction in end-products.

The Evidence

The strongest epidemiological evidence comes from a large longitudinal study by Steer et al.²² large longitudinal study by Steer et al.
Steer CD et al. Polyunsaturated fatty acid levels in blood during pregnancy, at birth and at 7 years: their associations with two common FADS2 polymorphisms. PLoS ONE, 2012 that followed 4,342 pregnant women through to their children at 7 years. The G allele showed strong positive associations with the substrates linoleic acid and alpha-linolenic acid, and corresponding negative associations with downstream highly unsaturated fatty acids including arachidonic acid, EPA, and DHA — at all three developmental time points studied (pregnancy, birth, and age 7).

A meta-analysis of 10 studies³³ meta-analysis of 10 studies
Liu et al. Meta-analysis of FADS2 rs174575 and long-chain PUFA levels. Br J Nutr, 2024 confirmed that G allele carriers have significantly elevated dihomo-γ-linolenic acid (P=0.005) and linoleic acid (P=0.002) alongside reduced arachidonic acid (P=0.033). In breast milk specifically, G allele carriers showed elevated dihomo-γ-linolenic acid (P=0.050) and reduced arachidonic acid (P=0.030) — directly relevant for infant nutrition.

A study of 250 pregnant women found that G allele carriers had significantly lower plasma EPA⁴⁴ G allele carriers had significantly lower plasma EPA
Carvalho GQ et al. Maternal polymorphisms in the FADS1 and FADS2 genes modify the association between PUFA ingestion and plasma concentrations of omega-3 polyunsaturated fatty acids. Clin Nutr, 2019 at moderate dietary LA/ALA ratios, with the genotype modifying how dietary omega-3 intake translates into circulating EPA levels.

Beyond fatty acid levels, FADS2 activity has downstream metabolic consequences. In Chinese Han individuals, G allele minor-allele carriers had lower erythrocyte arachidonic acid⁵⁵ G allele minor-allele carriers had lower erythrocyte arachidonic acid
Huang T et al. Genetic variants in desaturase gene, erythrocyte fatty acids, and risk for type 2 diabetes in Chinese Hans. Prostaglandins Leukot Essent Fatty Acids, 2014, and higher circulating omega-3 PUFAs were associated with lower type 2 diabetes risk.

Practical Implications

The critical implication of rs174575 G allele carriage is that plant-based omega-3 sources (flaxseed, chia seeds, walnuts, hemp) are much less useful than they would be for CC individuals. These foods supply ALA — but FADS2 must act first to begin converting ALA toward EPA and DHA. With impaired FADS2 activity, ALA accumulates rather than converting. Even at high dietary intakes, G allele carriers generate less EPA and DHA from plant sources than CC individuals at lower intakes.

This is particularly relevant for individuals on plant-based diets, where marine sources are excluded and the entire omega-3 strategy depends on conversion from ALA. For GG homozygotes on such diets, functional omega-3 deficiency is likely without targeted supplementation.

Breast milk composition is also affected — lactating G allele carriers produce milk with lower arachidonic acid and DHA, potentially impacting infant neurodevelopmental outcomes.

Interactions

rs174575 functions upstream in the FADS pathway from rs174547 (FADS1), which controls the subsequent delta-5 desaturation step. Individuals carrying G alleles at rs174575 and C alleles at rs174547 face a double bottleneck in the PUFA cascade — impaired delta-6 activity reduces the substrate available for delta-5 to convert, and then impaired delta-5 further reduces end-product yield. The practical effect is additive impairment of the entire endogenous pathway from LA/ALA to ARA/EPA/DHA.

rs1535 is another FADS2 intronic variant often studied alongside rs174575; the two are in moderate linkage disequilibrium in European populations, and rs1535 shows similar biological effects on PUFA levels.

The SHBG gene on chromosome 17 encodes sex hormone-binding globulin¹¹ sex hormone-binding globulin
a liver-produced transport protein that binds testosterone and estradiol in circulation. Only 1-2% of testosterone and estradiol circulate as "free" bioactive hormones — the rest is bound to SHBG (44%) or albumin (54%). By controlling how much hormone is bound versus free, SHBG acts as a master regulator of sex hormone activity throughout the body. The rs1799941 variant sits in the promoter region just upstream of the SHBG gene and directly influences how much SHBG protein the liver produces. This variant is particularly important because low SHBG levels are strongly associated with metabolic syndrome, type 2 diabetes, PCOS, and cardiovascular risk²² low SHBG levels are strongly associated with metabolic syndrome, type 2 diabetes, PCOS, and cardiovascular risk, while genetically higher SHBG levels may protect against these conditions — though with some unexpected trade-offs.

The Mechanism

Rs1799941 is a G-to-A polymorphism located in the regulatory promoter region of the SHBG gene on chromosome 17p12-p13³³ regulatory promoter region of the SHBG gene on chromosome 17p12-p13. The proximal promoter of SHBG contains binding sites for hepatocyte nuclear factor 4-alpha (HNF4A), which activates SHBG transcription⁴⁴ hepatocyte nuclear factor 4-alpha (HNF4A), which activates SHBG transcription. The A allele appears to enhance promoter activity, leading to increased SHBG production by liver hepatocytes. In population studies, each copy of the A allele increases serum SHBG levels by approximately 7-12 nmol/L⁵⁵ each copy of the A allele increases serum SHBG levels by approximately 7-12 nmol/L, with AA homozygotes showing 15-25% higher SHBG than GG homozygotes. Because SHBG binds testosterone with 5-fold higher affinity than estradiol, changes in SHBG levels disproportionately affect testosterone bioavailability — more SHBG means more testosterone gets locked up, reducing free testosterone even when total testosterone remains normal.

The Evidence

The largest study of rs1799941 is the Tromsø Study, which genotyped 5,309 Norwegian men and followed them for cardiovascular events, diabetes, cancer, and mortality⁶⁶ Tromsø Study, which genotyped 5,309 Norwegian men and followed them for cardiovascular events, diabetes, cancer, and mortality. Men with the AA genotype had 14.7% higher total testosterone and 24.7% higher SHBG compared to GG homozygotes, but crucially, free testosterone levels did not differ significantly between genotypes. The SNP was not significantly associated with myocardial infarction, type 2 diabetes, cancer, or mortality, suggesting that the A allele's protective effects on SHBG may be offset by reduced free testosterone bioavailability⁷⁷ the A allele's protective effects on SHBG may be offset by reduced free testosterone bioavailability.

A pediatric metabolic syndrome study in Turkish children found the opposite direction of effect⁸⁸ pediatric metabolic syndrome study in Turkish children found the opposite direction of effect — having at least one A allele associated with a 3-fold increased odds of metabolic syndrome (OR=3.09, p=0.006). Paradoxically, in control subjects the A allele increased SHBG levels (as expected), but in metabolic syndrome cases there was no association between genotype and SHBG, suggesting the mechanism through which rs1799941 affects SHBG is disrupted in metabolic disease.

A study of 212 young obese males investigated rs1799941 and hypogonadism risk⁹⁹ study of 212 young obese males investigated rs1799941 and hypogonadism risk. The A allele was associated with higher SHBG (AA genotype showed +12.45 nmol/L) but lower free testosterone (AA showed -18.52 pg/mL reduction). Importantly, the A allele increased the risk of presenting hypogonadism compared to normal free testosterone hypogonadism (OR=2.54). This reveals the double-edged nature of the variant — higher SHBG is generally metabolically protective, but if SHBG rises too high, it can reduce free testosterone to levels that trigger hypogonadal symptoms, especially in obese individuals.

In 558 women with polycystic ovary syndrome (PCOS), rs1799941 genotype was independently associated with SHBG levels after controlling for BMI, insulin resistance, and hyperandrogenism¹⁰¹⁰ 558 women with polycystic ovary syndrome (PCOS), rs1799941 genotype was independently associated with SHBG levels after controlling for BMI, insulin resistance, and hyperandrogenism. However, the SNP was not associated with PCOS status itself, suggesting it influences SHBG levels but doesn't directly cause PCOS. This is consistent with the understanding that PCOS is driven more by hyperinsulinemia and hyperandrogenism than by SHBG genetics.

Practical Implications

For carriers of the AA genotype, higher baseline SHBG production is generally protective against metabolic syndrome and insulin resistance. However, this comes with caveats. In obesity, the AA genotype may paradoxically increase hypogonadism risk by binding too much testosterone, leaving insufficient free testosterone for biological action. For women with PCOS, the variant influences SHBG levels but doesn't override the strong suppressive effects of hyperinsulinemia on SHBG — insulin resistance will drive SHBG down regardless of genotype. The GG genotype produces less SHBG baseline, which in lean individuals may optimize free testosterone availability, but in metabolic syndrome states this lower SHBG exacerbates the condition by allowing more free androgens to drive insulin resistance.

From a clinical standpoint, rs1799941 genotype helps explain why some individuals have relatively high or low SHBG despite similar metabolic profiles. AA individuals may benefit from monitoring free testosterone rather than total testosterone¹¹¹¹ AA individuals may benefit from monitoring free testosterone rather than total testosterone, particularly if obese, as their high SHBG can mask functional hypogonadism. GG individuals with low SHBG should be screened more aggressively for metabolic syndrome markers — fasting insulin, glucose, triglycerides, and waist circumference — as they are at higher baseline metabolic risk.

Interactions

Rs1799941 frequently interacts with other SHBG gene variants, particularly rs727428 and rs6259 (Asp327Asn), which also independently influence SHBG levels. Rs727428 and rs1799941 together account for significant variance in SHBG levels in PCOS women¹²¹² Rs727428 and rs1799941 together account for significant variance in SHBG levels in PCOS women, with compound effects observed when both variants are present. Additionally, the (TAAAA)n pentanucleotide repeat polymorphism in the SHBG promoter modulates the strength of rs1799941's effect — shorter repeats enhance promoter activity, amplifying the A allele's SHBG-raising effect. Beyond the SHBG gene, this variant's effects are modified by metabolic state — obesity, insulin resistance, and hepatic steatosis all suppress SHBG production through downregulation of HNF4A, potentially overwhelming the genetic effect of rs1799941. Thus, lifestyle factors (weight, exercise, diet) and metabolic health status significantly modulate the penetrance of this variant.